
|Videos|November 9, 2020
Bempedoic Acid
Author(s)Patrick Campbell
Advertisement
In this episode of Inside Cardiology, Practical Cardiology's Chief Advisory Board member Guy Mintz, MD, has a lengthy discussion with Steve Nissen, MD, of the Cleveland Clinic, related to bempedoic acid. A novel agent receiving approval in early 2020, bempedoic acid has the potential to help transform treatment algorithms for many lipidologists.
In the interview, Mintz has Nissen, who is also a principal investigator in the pivotal CLEAR program, dive deeper into the mechanism of action of bempedoic acid and where he believes it fits in the next set of guidelines on lipid management. Later in their discussion, Nissen offers insight into the highly-anticipated CLEAR Outcomes trial.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
5


























































